Literature DB >> 20593510

Hepatocellular carcinoma occurring in a Crohn's disease patient.

Mitsuaki Ishida1, Shigeyuki Naka, Hisanori Shiomi, Tomoyuki Tsujikawa, Akira Andoh, Tamio Nakahara, Yasuharu Saito, Yoshimasa Kurumi, Mikiko Takikita-Suzuki, Fumiyoshi Kojima, Machiko Hotta, Tohru Tani, Yoshihide Fujiyama, Hidetoshi Okabe.   

Abstract

We report a case of hepatocellular carcinoma (HCC) occurring in a patient with Crohn's disease (CD) without chronic hepatitis or liver cirrhosis, and review the clinicopathological features of HCC in CD patients. A 37-year-old Japanese man with an 8-year history of CD and a medication history of azathioprine underwent resection of a liver tumor. The histopathology of the liver tumor was pseudoglandular type HCC. In the non-neoplastic liver, focal hepatocyte glycogenosis (FHG) was observed, however, there was no evidence of liver cirrhosis or primary sclerosing cholangitis. Only nine cases of HCC in CD patients have been reported previously in the English-language literature. Eight of 10 cases (including the present case) had received azathioprine treatment, and four of these cases also showed FHG, which is considered a preneoplastic liver lesion, within the non-neoplastic liver. Although the precise mechanism of the development of HCC in CD patients is controversial, these results suggest that azathioprine therapy and FHG in the non-neoplastic liver contribute to the development of HCC. These findings also indicate that it is important to survey CD patients treated with prolonged azathioprine therapy for potential liver tumors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20593510      PMCID: PMC2896762          DOI: 10.3748/wjg.v16.i25.3215

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  18 in total

1.  Unusual development of hepatocellular carcinoma in a patient with Crohn's disease.

Authors:  M L Borum
Journal:  Dig Dis Sci       Date:  2001-10       Impact factor: 3.199

2.  Histological features predicting malignant transformation of nonmalignant hepatocellular nodules: a prospective study.

Authors:  S Terasaki; S Kaneko; K Kobayashi; A Nonomura; Y Nakanuma
Journal:  Gastroenterology       Date:  1998-11       Impact factor: 22.682

3.  De novo hepatocellular carcinoma without chronic liver disease but with 17 years of azathioprine immunosuppression.

Authors:  S Gruber; L P Dehner; R L Simmons
Journal:  Transplantation       Date:  1987-04       Impact factor: 4.939

4.  Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine.

Authors:  A Kandiel; A G Fraser; B I Korelitz; C Brensinger; J D Lewis
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

5.  Primary liver cell cancer occurring in association with Crohn's disease treated with prednisolone and azathioprine.

Authors:  F L Lee; S M Murray; J Prior; D R Shreeve
Journal:  Hepatogastroenterology       Date:  1983-10

6.  Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis.

Authors:  S Russmann; A Zimmermann; S Krähenbühl; B Kern; J Reichen
Journal:  Eur J Gastroenterol Hepatol       Date:  2001-03       Impact factor: 2.566

Review 7.  The risk of cancer in patients with Crohn's disease.

Authors:  Alexander C von Roon; George Reese; Julian Teare; Vasilis Constantinides; Ara W Darzi; Paris P Tekkis
Journal:  Dis Colon Rectum       Date:  2007-06       Impact factor: 4.585

8.  Living related donor liver transplantation for primary sclerosing cholangitis with hepatocellular carcinoma and Crohn's disease: a case report.

Authors:  H Oya; Y Sato; S Yamamoto; T Takeishi; T Kobayashi; K Hatakeyama
Journal:  Transplant Proc       Date:  2004-10       Impact factor: 1.066

9.  Hepatocellular carcinoma occurring in a patient with Crohn's disease treated with both azathioprine and infliximab.

Authors:  Shawn C Chen; Oscar W Cummings; Michael P Hartley; Carol A Filomena; Won Kyoo Cho
Journal:  Dig Dis Sci       Date:  2006-05-03       Impact factor: 3.199

10.  Azathioprine treatment increases hepatocyte turnover.

Authors:  N Arber; G Zajicek; J Nordenberg; Y Sidi
Journal:  Gastroenterology       Date:  1991-10       Impact factor: 22.682

View more
  7 in total

1.  Gut-liver axis plays a role in hepatocarcinogenesis of patients with Crohn's disease.

Authors:  Shu-Mei Zheng; De-Jun Cui; Qin Ouyang
Journal:  World J Gastroenterol       Date:  2011-07-14       Impact factor: 5.742

2.  Glycogenotic hepatocellular carcinoma with glycogen-ground-glass hepatocytes: a heuristically highly relevant phenotype.

Authors:  Peter Bannasch
Journal:  World J Gastroenterol       Date:  2012-12-14       Impact factor: 5.742

3.  Clinical features of hepatocellular carcinoma in patients with autoimmune hepatitis in Japan.

Authors:  Hiromasa Ohira; Kazumichi Abe; Atsushi Takahashi; Mikio Zeniya; Takafumi Ichida
Journal:  J Gastroenterol       Date:  2012-06-13       Impact factor: 7.527

4.  Metastatic hepatocellular carcinoma in a patient with Crohn's disease treated with azathioprine and infliximab: a case report and literature review.

Authors:  Kyle J Fortinsky; Ali Alali; Khursheed Jeejeebhoy; Sandra Fischer; Morris Sherman; Scott Fung
Journal:  Case Rep Gastrointest Med       Date:  2014-12-22

5.  Resected Hepatocellular Carcinoma in a Patient with Crohn's Disease on Azathioprine.

Authors:  Valérie Heron; Kyle Joshua Fortinsky; Gillian Spiegle; Nir Hilzenrat; Andrew Szilagyi
Journal:  Case Rep Gastroenterol       Date:  2016-05-19

6.  Recurrent Hepatocellular Carcinoma in Patient with Crohn's Disease: Incidental or Expected Outcome of Azathioprine?

Authors:  Youssef Botros; Mary Mathews; Hiren Patel; Nihar Shah; Walid Baddoura; Andrew de la Torre
Journal:  Case Rep Gastrointest Med       Date:  2015-12-14

Review 7.  Solid extraintestinal malignancies in patients with inflammatory bowel disease.

Authors:  Anastasia Mala; Kalliopi Foteinogiannopoulou; Ioannis E Koutroubakis
Journal:  World J Gastrointest Oncol       Date:  2021-12-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.